Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 6, 2025
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
GlobeNewswire
·
May 6, 2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
GlobeNewswire
·
May 6, 2025
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management …
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 6, 2025
-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company’s PI3Ka franchise with the planned announcement of a pan- …
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
GlobeNewswire
·
May 6, 2025
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. …
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
GlobeNewswire
·
May 6, 2025
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of …
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on …
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
GlobeNewswire
·
May 6, 2025
CELEBRATION, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate …
Bioventus Reports First Quarter Financial Results
GlobeNewswire
·
May 6, 2025
Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0% First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year period Non-GAAP earnings* of $0.08 per share increased 33% Company reiterated …
Neuronetics Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of …
Kraig Biocraft Laboratories Successfully Completes March/April Production Cycle; May Production Now Underway
GlobeNewswire
·
May 6, 2025
ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it has successfully completed its March/April spider silk …
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
The Joint Corp. Strengthens Management Appointing SVP Legal and SVP Operations and Patient Experience
GlobeNewswire
·
May 6, 2025
- Franchising legal specialist Andra J. Terrell with 20 years of experience in global master, single-unit and multi-unit franchising; compliance strategy; and financing, mergers, acquisitions, and divestitures- - Franchise operations leader Eric Wyatt with …
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
GlobeNewswire
·
May 6, 2025
-- PAS-004 shows up to 91% inhibition of pERK, confirming substantial target engagement -- -- One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable disease with tumor volume reduction of -9.8% -- MIAMI, …
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
GlobeNewswire
·
May 6, 2025
Cost-saving initiatives expected to extend company’s cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results …
Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients
GlobeNewswire
·
May 6, 2025
TPM502 achieved significant and dose-dependent reduction in IL-2 and IFN-γ release by gluten-specific T cells and durable immunomodulation of gluten-specific CD4+ T cells Patient-reported outcomes indicated dose-dependent reduction of symptoms following a …
Optima Health to acquire Care first
GlobeNewswire
·
May 6, 2025
Optima Health to acquire Care first, a leading provider of mental health services, for a net consideration of £15,000, adding c.£3.7 million revenue to the Group Acquisition provides Optima with increased scale in its Mental Health division and will …
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025
GlobeNewswire
·
May 6, 2025
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025 EBX-102-02 was well tolerated and demonstrated clinically meaningful improvements across multiple symptom domains in IBS-C patients Ph2b trial in IBS-C initiating in H2 2025 to …
MADD Canada’s Campaign 911 Urges People to Report Suspected Impaired Drivers, Riders and Boaters
GlobeNewswire
·
May 6, 2025
OAKVILLE, Ontario, May 06, 2025 (GLOBE NEWSWIRE) -- An impaired driver is an emergency. That’s the powerful message at the heart of MADD Canada’s Campaign 911, the national awareness program launching today to encourage Canadians to call 911 and report …
La Campagne 911 de MADD Canada exhorte les gens à signaler les conducteurs d’auto, de VTT et de bateau dont les capacités semblent affaiblies
GlobeNewswire
·
May 6, 2025
OAKVILLE, Ontario, 06 mai 2025 (GLOBE NEWSWIRE) -- Les conducteurs aux capacités affaiblies sont des situations d’urgence. C’est le puissant message au cœur de la Campagne 911 de MADD Canada, le programme de sensibilisation nationale, lancé aujourd’hui …
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference
GlobeNewswire
·
May 6, 2025
BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it …